Cyclerion Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYCN research report →
Price Chart
About the company
Cyclerion Therapeutics, Inc. operates as a biopharmaceutical company in the clinical development phase, concentrating on the discovery, advancement, and commercialization of therapeutic agents for debilitating central nervous system (CNS) disorders. Their leading experimental compound, CY6463, is a soluble guanylate cyclase (sGC) stimulator designed to cross the blood-brain barrier.
- CEO
- Regina Graul
- IPO
- 2019
- Employees
- 1
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on CYCN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $15.73M
- P/E
- -0.11
- PEG
- 0.00
- P/S
- 171.54
- P/B
- 0.01
- EV/EBITDA
- 5.17
- Div Yield
- 0.00%
- Gross Margin
- 25.56%
- Op Margin
- -5277.27%
- Net Margin
- -5088.39%
- ROE
- -50.57%
- ROIC
- -12.94%
Latest fiscal year · YoY change
- Revenue
- $2.07M+3.7%
- Gross Profit
- $2.07M+3.7%
- Op Income
- $-4,973,000
- Net Income
- $-3,528,000-15.4%
- EPS
- $-7.63+9.9%
- OCF Growth
- +23.5%
- FCF Growth
- +23.5%
- 52W High
- $59.36
- 52W Low
- $2.82
- 50D MA
- $26.37
- 200D MA
- $18.35
- Beta
- 1.75
- RSI (14)
- 50
- Avg Volume
- 8.06K
No earnings-call transcripts are available for CYCN yet.
- Free Float
- 67.1%
- Shares Outstanding
- 668.76K
- Float Shares
- 448.81K
of shares held by institutions
21 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fairmount Funds Management LLC | 9.10M | ▲ 9.10M |
| Tcg Crossover Management, LLC | 4.55M | ▲ 4.55M |
| Venrock Adviser, LLC | 4.55M | ▲ 4.55M |
| Fmr LLC | 3.20M | ▲ 2.55M |
| Jpmorgan Chase & Co | 2.69M | ▲ 2.69M |
| Fcpm Iii Services B.V. | 2.19M | ▲ 2.19M |
| Sanofi | 1.99M | ▲ 1.99M |
| Foresite Capital Management Vi LLC | 1.43M | ▲ 1.43M |
| General Atlantic, L.P. | 1.37M | ▲ 1.37M |
| Ra Capital Management, L.P. | 892.74K | ▲ 892.74K |
| Commodore Capital LP | 877.02K | ▲ 877.02K |
| Rtw Investments, LP | 877.02K | ▲ 877.02K |
Held by 20 ETFs
Biggest fund positions in CYCN by dollar value.
Our CYCN coverage
Recent articles, reports, and earnings notes.
No research on CYCN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYCN report →Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
globenewswire.com · Sep 8
Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?
prnewswire.com · Apr 9
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)
prnewswire.com · Apr 2
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
businesswire.com · Apr 2
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
prnewswire.com · Apr 1
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing
benzinga.com · Apr 1
Cyclerion Therapeutics, Inc. (CYCN) M&A Call Prepared Remarks Transcript
seekingalpha.com · Apr 1
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement
businesswire.com · Apr 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.